KemPharm Stock Price - KMPH

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
KemPharm Inc KMPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.206 0.00 0.00 0.00 0.206 20:00:00
Bid Price Ask Price Spread Spread % News
0.2101 0.2149 0.0048 2.23% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.206 USD

KemPharm Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 13.55M 65.76M 63.16M $ 12.84M $ - -0.91 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
635.83k $ - 0.00% - -

more financials information »

KemPharm News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical KMPH Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.280.3050.18910.23287567,740,845-0.074-26.43%
3 Months0.2210.43340.180.24835373,117,841-0.015-6.79%
6 Months0.43190.790.180.3131542,437,788-0.2259-52.3%
1 Year1.552.000.180.35938511,271,084-1.34-86.71%
3 Years4.458.400.180.9735068514,897-4.24-95.37%
5 Years14.16426.200.181.87341,548-13.96-98.55%

KemPharm Description

KemPharm Inc is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that believe will be improved versions of widely prescribed, approved drugs. The company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. Its LAT platform technology discovers and develops prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability, and safety. KemPharm's two lead product candidates are KP415, ER d-threo-methylphenidate product candidate for the treatment of ADHD, and KP201/IR, APAP-free, single-entity, benzhydrocodone hydrochloride IR abuse-deterrent product candidate designed for the treatment of acute pain.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.